Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
暂无分享,去创建一个
S. Hilsenbeck | R. Schiff | C. Osborne | A. Wakeling | S. Mohsin | Shoulei Jiang | M. Rimawi | A. Wakeling | S. Massarweh
[1] C. Osborne,et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.
[2] C. Osborne,et al. HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.
[3] X. Guan,et al. Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer , 2004, Clinical Cancer Research.
[4] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[5] D. El-Ashry,et al. A Cytoplasmic Substrate of Mitogen-Activated Protein Kinase Is Responsible for Estrogen Receptor-α Down-Regulation in Breast Cancer Cells: The Role of Nuclear Factor-κB , 2004 .
[6] R. Nicholson,et al. The Biology of Antihormone Failure in Breast Cancer , 2003, Breast Cancer Research and Treatment.
[7] Adrian V. Lee,et al. Crosstalk Between the Insulin-Like Growth Factors and Estrogens in Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.
[8] M. Dowsett,et al. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial , 2003 .
[9] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] G. Mills,et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.
[11] J. Baselga,et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[13] S. Pepe,et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] E. Levin,et al. Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.
[15] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[16] A. Wakeling,et al. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy. , 2002, Endocrine-related cancer.
[17] L. Björnström,et al. Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. , 2002, Molecular endocrinology.
[18] Carlos L. Arteaga,et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.
[19] Simak Ali,et al. Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.
[20] Arnab Chakravarti,et al. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.
[21] J. Slingerland,et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.
[22] Y. Lu,et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.
[23] R. Bianco,et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.
[24] R. Schiff,et al. Estrogen receptor: current understanding of its activation and modulation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] S. Cl,et al. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. , 2001 .
[26] N. Rosen,et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.
[27] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Dowsett,et al. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. , 2001, Endocrine-related cancer.
[29] M. Hung,et al. Correlation of p27 protein expression with HER‐2/neu expression in breast cancer , 2001, Molecular carcinogenesis.
[30] D. Agard,et al. Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[31] Sun,et al. Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signalling and growth in MCF-7 cells , 2000, European journal of cancer.
[32] M. Hung,et al. Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27* , 2000, The Journal of Biological Chemistry.
[33] Rakesh Kumar,et al. Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo1. , 2000, Endocrinology.
[34] C. Osborne,et al. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. , 1999, Endocrine-related cancer.
[35] J. Cheville,et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.
[36] V. Jordan,et al. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. , 1996, British Journal of Cancer.
[37] J. Robertson,et al. Oestrogen receptor: a stable phenotype in breast cancer. , 1996, British Journal of Cancer.
[38] S. Hilsenbeck,et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.
[39] C. Osborne,et al. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.
[40] J. Farndon,et al. EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.